drugset / Trial / NCT03794167
BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators developed a protocol comparing busulfan/cyclophosphamide/etoposide (BuCE) and busulfan/melphalan/etoposide (BuME) regimen as a conditioning for high-dose therapy (HDT) in the patients with high risk or relapsed Non-Hodgkin's Lymphoma (NHL).
Timeline
- Start
- 2012-06-01
- Primary completion
- 2017-05-30
- Completion
- 2018-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 3.2 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Subject | Etoposide | Small molecule | 400 mg/m2 | Intravenous |
| Comparator | Melphalan | Small molecule | 50 mg/m2 | Intravenous |